96977 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Cytokines; Lymphokines; Interferons Interferons [IFN]
Sub-classes:CRYSTALLISATION OF A PROTEIN CAPABLE OF CRYSTALLIZING UNDER SALTING-IN CONDITIONS USING MULTIPLE PROTEIN FEEDS
#2COMBINATION OF MACROPHAGE-DIRECTED IMMUNOTHERAPY AND CYTOKINES FOR TREATMENT OF CANCER
#3THANOTRANSMISSION POLYPEPTIDES AND THEIR USE IN TREATING CANCER
#4ALU SINES OF THE MIR-498(46) CISTRON MEDIATE INTRINSIC INTERFERON AND ANTIVIRAL RESPONSE IN HUMAN PLACENTA
#5CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
#6USE OF IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS
#7Modified RELA Protein for Inducing Interferon Expression and Engineered Immune Cells with Improved Interferon Expression
#8DOSAGE REGIMEN FOR PEGYLATED INTERFERON
#9CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
#10FUSION PROTEIN OF INTERFERON (IFN) AND ANTI-PD-L1 ANTIBODY AND USE THEREOF
#11PROTEIN SIGNATURES FOR DISTINGUISHING BETWEEN BACTERIAL AND VIRAL INFECTIONS
#12INTERFERON RECEPTOR ANTAGONISTS AND USES THEREOF
#13Heterohexameric Fusion Constructs for Protein Expression in Cyanobacteria
#14ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF
#15MODIFIED TNF AS A CAPTURE LIGAND
#16IMMUNOCYTOKINES AND USES THEREOF
#17MODULATION OF IFI16 AND STING ACTIVITY
#18USE OF IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS
#19ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF
#20ANTI-NKP30 ANTIBODY AND APPLICATION THEREOF
#21FIBROBLAST BINDING AGENTS AND USE THEREOF
#22GENETICALLY ENGINEERED ELECTRICALLY-STIMULATED EFFECTOR CELLS FOR IN SITU SYNTHESIS OF PROTEINS
#23METHOD FOR PRODUCING CHIMERIC ANTIGEN RECEPTOR-MACROPHAGES AND USE OF SAME CELLS
#24INTERFERON TAU FC-FUSION PROTEINS AND METHODS FOR TREATING CORONAVIRUS INFECTIONS
#25CELL-BASED THERAPY FOR VIRAL DISEASES
#26INTERLEUKIN-2 PROPROTEINS AND USES THEREOF
#27INTER-APPLICATION WORKFLOW PERFORMANCE ANALYTICS
#28METHOD FOR PURIFICATION OF RECOMBINANT PROTEINS
#29Method for preparing a porcine-derived interferon-delta 5 and application of porcine-derived interferon-delta 5
#30Interferon-associated antigen binding proteins and uses thereof
#31INTERFERON-ASSOCIATED ANTIGEN BINDING PROTEINS AND USES THEREOF
#32PROPROTEINS AND METHODS OF USE THEREOF
#33TREATMENT OF DISEASES WITH CLEVER-1 INHIBITION IN COMBINATION WITH AN INTERLEUKIN INHIBITOR
#34IMMUNE EFFECTOR CELL IN WHICH EXPRESSION IS REGULATED BY CYTOKINES
#35DOSAGE REGIMEN FOR PEGYLATED INTERFERON
#36NOVEL INTERFERON LAMBDA VARIANT AND METHOD OF PRODUCING THE SAME
#37PROPROTEINS AND METHODS OF USE THEREOF
#38IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
#39CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
#40Modified TNF as a capture ligand
#41THANOTRANSMISSION POLYPEPTIDES AND THEIR USE IN TREATING CANCER
#42MODIFIED IFNL3 POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY AND THEIR USES
#43Long-acting polypeptides and methods of producing and administering same
#44METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN
#45Oncolytic virus expressing interferon and application therefor
#46VARIANT TYPE III INTERFERONS AND SYNTHEKINES
#47Protein signatures for distinguishing between bacterial and viral infections
#48IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
#49METHODS OF PRODUCING LONG ACTING CTP-MODIFIED POLYPEPTIDES
#50In vivo protein N-acylation
#51METHODS OF DETERMINING INTERFERON HAVING DIRECT INHIBITORY EFFECTS ON TUMORS AND USES THEREOF
#52TUMOR-SPECIFIC IFNA SECRETION BY CAR T-CELLS TO REPROGRAM THE SOLID TUMOR MICROENVIRONMENT
#53TARGETED ENGINEERED INTERFERON AND USES THEREOF
#54Fusion protein of interferon (IFN) and anti-PD-L1 antibody and use thereof
#55ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF
#56Fusion Proteins Containing CD47 Antibodies and Cytokines
#57Fibroblast binding agents and use thereof
#58RECOMBINANT HUMAN INTERFERON-LIKE PROTEINS
#59METHODS AND SYSTEMS FOR PROTEIN REFOLDING
#60PROPROTEINS AND METHODS OF USE THEREOF
#61A NOVEL INTERFERON-(lambda)4 (IFNL-4) PROTEIN, RELATED NUCLEIC ACID MOLECULES, AND USES THEREOF
#62METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN
#63Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
#64IgG binding peptides and multifunctional antigen-binding proteins comprising the same
#65Phosphatidylserine targeting fusion molecules and methods for their use
#66CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
#67Use of lambda interferons in the treatment of obesity-related disorders and related diseases
#68CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
#69CD40 AGONIST ANTIBODY /TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY
#70Immunoglobulin chimeric monomer-dimer hybrids
#71In vivo protein N-acylation
#72Interferon Analogs
#73Fusion polypeptides and methods of use
#74BCMA-targeting antibody and use thereof
#75Polypeptide derivatives from grass carp interferon and application thereof
#76Method of treatment ovarian cancer
#77Methods of treating a disorder associated with with insufficient stimulator of interferon genes (STING) activity
#78Compositions comprising desaminotyrosine and uses thereof to enhance type I interferon stimulation
#79CYSTEINE VARIANTS OF INTERLEUKIN-11 AND METHODS OF USE THEREOF
#80Variant type III interferons and synthekines
#81METHODS AND SYSTEMS FOR PROTEIN REFOLDING
#82Protein signatures for distinguishing between bacterial and viral infections
#83Immunity-inducing agent
#84Method of treating diseases with recombinant human interferon-like proteins
#85Immunity-inducing agent
#86Tumor-specific IFNA secretion by car T-cells to reprogram the solid tumor microenvironment
#87Interferon analogs
#88RECOMBINANT SUPER-COMPOUND INTERFERON AND USES THEREOF
#89Long-acting polypeptides and methods of producing and administering same
#90Methods for increasing levels of interferon activity with an interferon lambda 3 polypeptide
#91LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING SAME
#92Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
#93METHODS OF PRODUCING LONG ACTING CTP-MODIFIED GROWTH HORMONE POLYPEPTIDES
#94METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN
#95Affinity chromatography wash buffer
#96Method to increase the number of circulating platelets by administering PEGylated cysteine variants of IL-11
#97Dosage regimen for pegylated interferon
#98Immunoglobulin chimeric monomer-dimer hybrids
#99Interferon-λ4 (IFNL-4) protein, related nucleic acid molecules, and uses thereof
#100Cleavage-activatable interferon-alpha proprotein
#101GENETICALLY MODIFIED MESENCHYMAL STEM CELLS EXPRESSING AN IMMUNE RESPONSE-STIMULATING CYTOKINE TO ATTRACT AND/OR ACTIVATE IMMUNE CELLS
#102Targeted interferons demonstrate potent apoptotic and anti-tumor activities
#103METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN
#104Fusion polypeptides and methods of use
#105Recombinant human interferon-like proteins
#106Long-acting polypeptides and methods of producing and administering same
#107Method for increasing interferon activity in an individual
#108Protein production systems and methods thereof
#109METHODS OF PRODUCING LONG ACTING CTP-MODIFIED POLYPEPTIDES
#110Interferon lambda-antibody complexes
#111Method for producing natively folded proteins in a prokaryotic host
#112Method for producing soluble recombinant interferon protein without denaturing
#113Nucleic acid construct encoding an agonistic anti-CD40 antibody and a type I interferon
#114Albumin fusion proteins
#115Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
#116Soluble notch receptor proproteins and methods of use thereof
#117Long-acting polypeptides and methods of producing same
#118Long-acting polypeptides and methods of producing same
#119Long-acting polypeptides and methods of producing and administering same
#120METHOD FOR HARVESTING ORGANIC COMPOUNDS FROM GENETICALLY MODIFIED ORGANISMS
#121Long-acting polypeptides and methods of producing and administering same
#122Immunoglobulin chimeric monomer-dimer hybrids
#123Long-acting polypeptides and methods of producing and administering same
#124Long-acting polypeptides and methods of producing and administering same
#125Interferon-λ4 (IFNL4) protein, related nucleic acid molecules, and uses thereof
#126USE OF NEW RECOMBINANT INTERFERONS WITH ALTERED SPATIAL CONFIGURATION AND THREE-DIMENSIONAL STRUCTURE
#127Modified SAK gene for the production of recombinant proteins
#128Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof
#129Recombinant fusion interferon for animals
#130METHODS AND SYSTEMS FOR PROTEIN REFOLDING
#131METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN
#132HUMAN FUSION PROTEINS COMPRISING INTERFERONS AND TARGETED MODIFIED UBIQUITIN PROTEINS
#133Drug monitoring methods using the promyelocytic leukemia protein as a redox sensor
#134Mutants of IL-29
#135DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS
#136Targeted interferons demonstrating potent apoptotic and anti-tumor activities
#137Treatment of tumors with recombinant interferon alpha
#138Recombinant fusion interferon for animals
#139Recombinant fusion interferon for animals
#140Anticancer fusion protein comprising TRAIL and interferon
#141PEG-interferon λ1 conjugates and methods of treating viral infections
#142Recombinant human interferon-like proteins and method of treatment using them
#143DESIGN AND USE OF NEW RECOMBINANT INTERFERONS WITH ALTERED SPATIAL CONFIGURATION AND THREE-DIMENSIONAL STRUCTURE
#144Long-acting polypeptides and methods of producing and administering same
#145Immunoglobulin chimeric monomer-dimer hybrids
#146Interferon lambada-antibody complexes
#147Modified SAK gene for the production of recombinant proteins
#148Proproteins activatable interferon alpha
#149Interferon analogs
#150High Pressure Treatment of Aggregated Interferons
#151Promyelocytic leukemia protein as a redox sensor
#152Recombinant protein production in heterologous systems
#153DESIGN AND USE OF NEW RECOMBINANT INTERFERONS WITH ALTERED SPATIAL CONFIGURATION AND THREE-DIMENSIONAL STRUCTURE
#154Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof
#155Monkey homolog of human interferon omega
#156Selection and characterization of novel plant-derived recombinant human interferons with broad spectrum activity
#157Consensus interferon variant and methods of suppressing viral activity
#158Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
#159Method for producing proteins in that lack detectable cross binding activity to antibodies against host cell antigens
#160Method for producing natively folded proteins in a prokaryotic host
#161Antiviral activity of bovine type III interferon against foot-and-mouth disease virus
#162INTERFERON-LIKE PROTEINS AND USES THEREOF
#163Interferon-lambda 1 polypeptides
#164Albumin fusion proteins
#165Long-acting polypeptides and methods of producing same
#166Long-acting veterinary polypeptides and methods of producing and administering same
#167Method of using IL-29 cystehne mutant to treat hepatitis C and hepatitis B
#168Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
#169Cysteine variants of interferon gamma
#170Type I Interferon Antagonists
#171Therapeutic agent for hematopoietic tumors
#172Method for producing soluble recombinant interferon protein without denaturing
#173Treatment of tumors with recombinant interferon alpha
#174Immunoglobulin chimeric monomer-dimer hybrids
#175USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS
#176IFN-ALPHA/BETA-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION THROUGH A NOVEL LIGAND-RECEPTOR PAIR: IFN- LIGANDS ENGAGE A NOVEL RECEPTOR IFN-RN (CRF2-12) AND IL-10R2 (CRF2-4) FOR SIGNALING ANDINDUCTION OF BIOLOGICAL ACTIVITIES
#177Methods for Chemically Synthesizing Immunoglobulin Chimeric Proteins
#178Crystalline recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof
#179Protease resistant modified IFN beta polypeptides and their use in treating diseases
#180Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities
#181Avian cytokines and genetic sequences encoding same
#182Albumin fusion proteins
#183HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE
#184Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
#185INTERFERON LAMBDA FUSION POLYPEPTIDES
#186Recombinant human interferon-like proteins
#187Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities
#188NEW TYPE OF CONSENSUS INTERFERON AND PREPARATION METHOD THEREOF
#189PEG-interferon-beta formulations
#190INTERFERONS, USES AND COMPOSITIONS RELATED THERETO
#191Protease activatable interferon alpha proprotein
#192Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities
#193Human Interferon Molecules and Their Uses
#194Recombinant human interferon-like proteins
#195Interferon alpha and interferon kappa fusion protein
#196HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29
#197Recombinant human interferon-like proteins
#198Novel Vectors for Production of Interferon
#199Treatment of viral diseases with recombinant interferon α
#200Long-acting polypeptides and methods of producing same
#201Long-acting veterinary polypeptides and methods of producing and administering same
#202Long-acting EPO polypeptides and derivatives thereof and methods thereof
#203Polynucleotides encoding long-acting growth hormone polypeptides and methods of producing same
#204IRX-2 modified manufacturing process
#205IFN-λ polypeptides and compositions
#206High pressure treatment of aggregated interferons
#207MOLECULE AND CHIMERIC MOLECULES THEREOF
#208Protease resistant modified erythropoietin polypeptides
#209Interferon-β mutants with increased anti-proliferative activity
#210Treatment of tumors and viral diseases with recombinant interferon alpha
#211Albumin Fusion Proteins
#212Albumin Fusion Proteins
#213DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS
#214Protease resistant modified interferon-beta polypeptides
#215Cysteine variants of interferon gamma
#216Recombinant human interferon-like proteins
#217Treatment of viral diseases with recombinant interferon α
#218Method of using IL-29 cysteine mutant to treat hepatitis C and hepatitis B
#219Protease resistant interferon beta mutants
#220Methods for chemically synthesizing immunoglobulin chimeric proteins
#221Cysteine variants of interferon-gamma
#222Albumin fusion proteins
#223Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
#224Method for reducing the immune response to a biologically active protein
#225Albumin Fusion Proteins
#226Albumin fusion proteins comprising insulin polypeptides
#227Albumin Fusion Proteins
#228Method for producing protein
#229Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
#230G-CSF-albumin fusion proteins
#231Albumin fusion proteins
#232Pegylated human interferon polypeptides
#233Uses of Recombinant Super-Compound Interferons
#234Human Interferon Molecules and Their Uses
#235Human Interferon Molecules and Their Uses
#236Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
#237System for High Production of Natural and Personalized Interferons
#238Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
#239Albumin fusion proteins
#240Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
#241Method of stabilizing proteins
#242Albumin fusion proteins
#243Methods for treating cancer using interferon-ω-expressing polynucleotides
#244Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
#245Long-acting polypeptides and methods of producing same
#246Long-acting EPO polypeptides and derivatives thereof and methods thereof
#247Long-acting veterinary polypeptides and methods of producing and administering same
#248Immunoglobulin chimeric monomer-dimer hybrids
#249Polynucleotide encoding an IL-28B polypeptide
#250Protease resistant interferon beta mutants
#251Homogeneous preparations of IL-28 and IL-29
#252Interferon antagonists useful for the treatment of interferon related diseases
#253Homogeneous preparations of IL-28 and IL-29
#254Amniotic-derived peptide and uses thereof
#255HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29
#256HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29
#257HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29
#258Homogeneous preparations of IL-28
#259Polynucleotide encoding an IL-28B polypeptide
#260HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29
#261HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29
#262HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29
#263HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29
#264Homogeneous preparations of IL-28 and IL-29
#265Polynucleotide encoding an IL-28A polypeptide
#266Polynucleotide encoding an IL-28A polypepide
#267Polynucleotide encoding an IL-29 polypeptide
#268Polynucleotide encoding an il-29 polypeptide
#269Homogeneous preparations of IL-28A cysteine mutants
#270HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29
#271Polynucleotide encoding an IL-28B polypeptide
#272Homogeneous preparations of IL-28 and IL-29
#273Homogeneous preparations of IL-28A mutants
#274Homogeneous preparations of IL-28 A
#275Homogeneous preparations of IL-28A cysteine mutants
#276Homogeneous preparations of IL-28 and IL-29
#277HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29
#278Polynucleotide encoding an IL-28A polypeptide
#279Polynucleotide encoding an IL-28B polypeptide
#280Polynucleotide encoding an IL-29 polypeptide
#281HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29
#282Polynucleotide encoding an IL-28A polypeptide
#283Methods for reduction of scar tissue formation
#284Albumin fusion proteins
#285Interferon-IgG fusion
#286Materials and methods for inhibition of IgE production
#287Hyperglycosylated polypeptide variants and methods of use
#288Albumin fusion proteins
#289Peptides and recombinant proteins mimicking interferons
#290IFN receptor 1 binding proteins
#291Modified cytokines for use in cancer therapy
#292Therapeutic agent for hematopoietic tumors
#293Long acting human interferon analogs
#294Recombinant super-compound interferon and uses thereof
#295Interferon-like proteins and uses thereof
#296Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
#297Immunoglobulin chimeric monomer-dimer hybrids
#298Cysteine substitution variants of beta interferon
#299Interferon-like molecules and uses thereof
#300COOH-terminally added cysteine variant of the beta interferon